Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection – DocWire News

This article was originally published here

Stem Cells Transl Med. 2020 Nov 14. doi: 10.1002/sctm.20-0385. Online ahead of print.

ABSTRACT

Anti-inflammatory and immune-modulatory therapies have been proposed for the treatment of COVID-19 and its most serious complications. Among others, the use of mesenchymal stromal cells (MSCs) is under investigation given their well-documented anti-inflammatory and immunomodulatory properties. However, some critical issues regarding the possibility that MSCs could be infected by the virus have been raised. Angiotensin-converting enzyme 2 (ACE2) and type II transmembrane serine protease (TMPRSS2) are the main host cell factors for the Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) entry but so far it is unclear if human MSCs express or do not these two proteins. To elucidate these important aspects, we evaluated if human MSCs from both fetal and adult tissues constitutively express ACE2 and TMPRSS2 and, most importantly, if they can be infected by SARS-CoV-2. We evaluated human MSCs derived from amnios, cord blood, cord tissue, adipose tissue and bone marrow. ACE2 and TMPRSS2 were expressed by the SARS-CoV-2-permissive human pulmonary Calu-3 cell line but not by all the MSCs tested. MSCs were then exposed to SARS-CoV-2 wild strain without evidence of cytopathic effect. Moreover, we also excluded that the MSCs could be infected without showing lytic effects since their conditioned medium after SARS-CoV-2 exposure did not contain viral particles. Our data, demonstrating that MSCs derived from different human tissues are not permissive to SARS-CoV-2 infection, support the safety of MSCs as potential therapy for COVID-19. AlphaMed Press 2020 SIGNIFICANCE STATEMENT: Human mesenchymal stromal cells (hMSCs) are currently under investigation for the treatment of COVID-19. However, the potential safety profile of hMSCs in this context has never been defined since none has described if they express ACE2 and TMPRSS2, the main host cell factors for SARS-CoV-2 entry, and if they can be infected by SARS-CoV-2. We provide the first evidence that ACE2 and TMPRSS2 are not expressed in hMSCs derived from both adult and fetal human tissues and, most importantly, that hMSCs are not permissive to SARS-CoV-2 infection. These results support the safety of MSCs as potential therapy for COVID-19.

PMID:33188579 | DOI:10.1002/sctm.20-0385

See the article here:
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News

Cynata Therapeutics (ASX:CYP) begins phase three osteoarthritis trial – The Market Herald

Cynata Therapeutics (CPY) has begun its phase three osteoarthritis clinical trial using its Cymerus mesenchymal stem cell (MSC) product, CYP-004.

The trial is sponsored by the University of Sydney and is funded by an Australian Government National Health and Medical Research Council (NHMRC) grant.

It will take place at study centres in Sydney and Tasmania and will begin with an initial four patients who will be assessed over a four week period.

Once completed, the study will open for a wider enrolment.

The aim of the trial is to assess the effect of Cymerus MSCs on the knee joint structure over a two-year period in 440 patients with osteoarthritis in the area.

The trial will be led by the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney, Professor David Hunter.

It also includes Professor Changhai Ding from the University of Tasmania, Professor Stefan Lohmander from the Lund University in Sweden, and Dr Rachel O'Connor and Dr Xia Wang from the University of Sydney.

"There is now cure for osteoarthritis and current treatment options largely focus on alleviating pain rather than modifying the course of the underlying disease," Professor David stated.

"We are delighted to commence this trial, which is designed to evaluate the disease modifying potential of Cymerus MSCs. Consequently, we anticipate that it will be an enormously influential trial, with the potential to inform clinical practice guidelines globally," he added.

MSCs are adult stem cells found in a wide range of human tissue such as bone marrow, placenta and fat tissue.

They are multi-potent, which means they can produce more than one type of cell. For example, they can differentiate into cartilage cells, fat cells, and bone cells.

They have been shown to ease regeneration and effects on the immune system without relying on engraftment (when transplanted cells start to grow and make healthy cells).

Patients will receive either an intra-articular injection of Cymerus MSCs or a placebo three times during a one year period. This will then followed-up for a two year period post enrolment.

Cynata will measure the quality of life, assessment of pain, physical function, and the proportion of participants achieving patient-acceptable symptom state - which is the highest level in which patients consider themselves satisfied with treatment.

"This clinical trial aims to determine whether Cynata's proprietary Cymerus MSC technology is active in the setting of knee osteoarthritis," Chief Operating Officer Dr Killian Kelly said.

"We look forward to advancing this clinical trial to investigate the potential benefits our MSCs could have to treat osteoarthritis patients with this common and debilitating disease," he added.

Cynata has ended the day 6.55 per cent in the green, with shares trading for 89.5 cents each in a $98.38 million market cap.

Excerpt from:
Cynata Therapeutics (ASX:CYP) begins phase three osteoarthritis trial - The Market Herald

$ 30.1 billion Worth Cell Expansion Market, Led by Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Terumo BCT and Others. re:Jerusalem -…

ReportsnReports offers a global report on Cell Expansion Market delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 354 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Browse 595 Market Data Tables and 33 Figures spread through 354 Pages and in-depth TOC on Cell Expansion Market Research Report https://www.reportsnreports.com/contacts/requestsample.aspx?name=313419

The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), Terumo BCT (Japan), Merck KGaA (Germany), Danaher Corporation (US), MiltenyiBiotec (Germany), Lonza Group Ltd. (Switzerland), STEMCELL Technologies Inc. (Canada), GE Healthcare (US), and Corning, Inc. (US).

Consumables accounted for the larger share of the cell expansion market in 2018

On the basis of products, the cell expansion market is segmented into consumables and instruments. Consumables are segmented into reagents, media, sera, and disposables. The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems. In 2018, consumables accounted for the largest share of the cell expansion products market owing to the constant requirement for new reagents among end users and rising investments for R&D on cell-based therapies.

Inquire for DISCOUNT on Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End User, and Region Global Forecast to 2024 research report at https://www.reportsnreports.com/contacts/discount.aspx?name=313419

Human cells accounted for the largest share of the cell expansion market in 2018

Based on cell type, the cell expansion market is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. These cells are used for therapeutic and research purposes. In 2018, the human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

North America dominates the cell expansion market

North America, which includes the US and Canada, accounted for the largest share of the cell expansion in 2018.The large share of this market segment can be attributed to the government funding for cancer research, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Order a copy of Cell Expansion Market research report at https://www.reportsnreports.com/purchase.aspx?name=313419

Breakdown of supply-side primary interviews, by company type, designation, and region:

Continued here:
$ 30.1 billion Worth Cell Expansion Market, Led by Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Terumo BCT and Others. re:Jerusalem -...

Impact of COVID-19 on Advanced Wound Care Management Market : Implications on Business Strategies, Countermeasures, Economic Impact – The Think…

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=132

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

Buy Report Now :https://www.transparencymarketresearch.com/checkout.php?rep_id=132&ltype=S

This review is based on the findings of a TMR report, titled, Stem Cells Market (Product Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem; Sources Autologous and Allogeneic; Application Regenerative Medicine and Drug Discovery and Development; End Users Therapeutic Companies, Cell and Tissues Banks, Tools and Reagent Companies, and Service Companies) Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 20172025.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The Stem Cells Market is segmented as below:

Global Stem Cells Market, by Product Type

Global Stem Cells Market, by Source

Global Stem Cells Market, by Application

Global Stem Cells Market, by End Users

Global Stem Cells Market, by Geography

More Trending Reports by Transparency Market Research 1.http://www.prnewswire.com/news-releases/increasing-number-of-accidents-and-injuries-to-drive-adoption-of-wound-closure-strips-market-valuation-to-rise-up-to-us446-3-mn-by-2027-end-finds-tmr-301019647.html

2.https://www.biospace.com/article/atopic-dermatitis-drugs-market-exponential-growth-of-biologic-drugs-favor-market-growth/

Original post:
Impact of COVID-19 on Advanced Wound Care Management Market : Implications on Business Strategies, Countermeasures, Economic Impact - The Think...

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease – DocWire News

This article was originally published here

N Engl J Med. 2020 Oct 27. doi: 10.1056/NEJMoa2026834. Online ahead of print.

ABSTRACT

BACKGROUND: Adult-onset inflammatory syndromes often manifest with overlapping clinical features. Variants in ubiquitin-related genes, previously implicated in autoinflammatory disease, may define new disorders.

METHODS: We analyzed peripheral-blood exome sequence data independent of clinical phenotype and inheritance pattern to identify deleterious mutations in ubiquitin-related genes. Sanger sequencing, immunoblotting, immunohistochemical testing, flow cytometry, and transcriptome and cytokine profiling were performed. CRISPR-Cas9-edited zebrafish were used as an in vivo model to assess gene function.

RESULTS: We identified 25 men with somatic mutations affecting methionine-41 (p.Met41) in UBA1, the major E1 enzyme that initiates ubiquitylation. (The gene UBA1 lies on the X chromosome.) In such patients, an often fatal, treatment-refractory inflammatory syndrome develops in late adulthood, with fevers, cytopenias, characteristic vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary inflammation, chondritis, and vasculitis. Most of these 25 patients met clinical criteria for an inflammatory syndrome (relapsing polychondritis, Sweets syndrome, polyarteritis nodosa, or giant-cell arteritis) or a hematologic condition (myelodysplastic syndrome or multiple myeloma) or both. Mutations were found in more than half the hematopoietic stem cells, including peripheral-blood myeloid cells but not lymphocytes or fibroblasts. Mutations affecting p.Met41 resulted in loss of the canonical cytoplasmic isoform of UBA1 and in expression of a novel, catalytically impaired isoform initiated at p.Met67. Mutant peripheral-blood cells showed decreased ubiquitylation and activated innate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in zebrafish caused systemic inflammation.

CONCLUSIONS: Using a genotype-driven approach, we identified a disorder that connects seemingly unrelated adult-onset inflammatory syndromes. We named this disorder the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. (Funded by the NIH Intramural Research Programs and the EU Horizon 2020 Research and Innovation Program.).

PMID:33108101 | DOI:10.1056/NEJMoa2026834

Go here to see the original:
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News

Stem Cells Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 – Zenit News

Final Report will add the analysis of the impact of COVID-19 on this industry.

The report provides the forecast of the Stem Cells Market for the next four years which assist Stem Cells industry analyst for building and developing business strategies. The Stem Cells market report contains industry top manufacturers discussion based on the companys profiles, financial analysis, overview, market revenue, and opportunities by top geographical regions.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/14325305

The Stem Cells Market Report is an in-depth assessment of current state of industry and estimates forecast based on actual facts and figures. The Stem Cells Market report provides analysis based on segmentations, market potential, influential trends, and the challenges that the market is facing during this COIVD- 19 pandemic. The data (tables, figures, statistics, numbers) about the Stem Cells market are taken from trustworthy sources such as websites, yearly reports of the enterprises, journals, and others and were tested and validated by the expert`s.

To Understand How COVID-19 Impact is Covered in this Report Click Here

This research consists of market segmentation by Types, Application and Stem Cells market division based on geographical locations. Report also segmented by top vendors provides data about company introduction, product specification and major types analysis, production market performance, sales market performance and contact information:

By Market Players: Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., BrainStorm Cell Therapeutics Inc., U.S. Stem Cell, Inc., Takara Bio Inc., BioTime Inc., Cellular Engineering Technologies Inc., Astellas Pharma Inc., Caladrius Biosciences, Inc., STEMCELL Technologies Inc.

By Product Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell

By Source Autologous, Allogeneic,

By Application Regenerative Medicine, Drug Discovery and Development,

By End User Therapeutic Companies, Cell and Tissue Banks, Tools and Reagent Companies, Service Companies,

Regional Analysis Covers: USA, Europe, China, India, Southeast Asia, Japan, South America, South Africa, Others.

The Stem Cells market research report is a resource, which provides current as well as upcoming technical and financial details of the industry. The detailed study in this report enables CEOs, traders, investors, and dealers to realize the market in a better way and based on that data make knowledgeable decisions.

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/14325305

Points Covered in the Stem Cells Market Report:

Who are Key Manufacturers: Major market players that are concerned within the market like manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

Data regarding Key Companies: Stem Cells Capability, production, price, revenue, cost, gross, profit margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and also the technological developments.

Segmentation Analysis: Stem Cells Information and data by manufacturer, by region, by type, by application and etc. The report contains the SWOT analysis of the market.

Important Questions Answered in Stem Cells Market Report:

Purchase This Report (Price 3500 USD for single user license) https://www.industryresearch.co/purchase/14325305

In short TOC of 2019-2024 Global and Regional Stem Cells Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report

-Stem Cells overview includes Brief Introduction by Major Type, Application, Region

-Production analysis includes Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

-Stem Cells Sales analysis contains Global Sales Volume, Sales Price and Sales Revenue Analysis

-Consumption of Stem Cells Market Analysis by Regional Market Performance and Market Share

-Stem Cells Regional Market Performance and Market Share

-New Project Investment Feasibility Analysis contains SWOT Analysis

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Industry Research Co.

Phone: +14242530807/+44203239 8187

Our Other Reports:

Novaluron Market Potential Risks and Comprehensive Competitive Strategy Analysis in Different Fields, Report 2020 to 2025

Global Dermatology Diagnostic Devices and Therapeutics Market Size 2020 to 2025 Report Includes Brief Analysis by Regions, Growth Key Factors, Demand, Business Share

High-Strength Epoxy Adhesives Market Size Insight Report 2020 to 2026 by Manufactures Types, End Users and Regions with COVID-19 Impact Analysis

High Chrome Mill Internals (Hcmis) Market 2020 Report with Rapidly Growing CAGR at 10.22% Industry Size, Share, Revenue and Outlook to 2025

Amniotic Membrane Market Size 2020 Industry Research, Share, Analysis, Demand, Growth, Segmentation, Manufacturers, Forecasts to 2026

Seam Tapes Market Outlook to 2026 Emerging Trends and Will Generate New Growth Opportunities Status

License Plate Capture Cameras Market Size 2020 Industry Research, Share, Analysis, Demand, Growth, Segmentation, Manufacturers, Forecasts to 2026

Radio Frequency Detector Market Size 2020 Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2026

Allergy Immunotherapy Market Size by Regional Production Volume, Consumption Volume, Revenue and Growth Rate to 2026

Global ESD Suppressors Market Size 2020 Company Overview, Growth and Forecast By 2026 Latest Research Report by Industry Research Co

Dry Honey Product Market Size, Cost Analysis, Revenue and Gross Margin Analysis with Its Important Types and Application to 2026

See the original post here:
Stem Cells Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 - Zenit News

JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double…

OCEANSIDE, Calif., Oct. 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today a publication from the University of Miami1, demonstrating intravenous administration of JadiCells results in a significant survival improvement in COVID-19 patients. The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells intravenously at days 0 and 3, and 12 patients received placebo control. At 28 days 91% of JadiCell treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell administration.

"In July of 2019, we obtained an exclusive license for the use of JadiCells in treatment of chronic traumatic encephalopathy (CTE) and brain injury2. Since then we have been working diligently at developing an IND file for initiation of clinical trials" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "The data reported today strongly supports further clinical translation of JadiCells. Not only do these data support safety of intravenous administration, but also attest to the potent anti-inflammatory and regenerative effects of this unique stem cell population."

JadiCells are a type of "supercharged" mesenchymal stem cells which have been demonstrated by the Company, as well as independent academic and private institutions to possess superior therapeutic activity as compared to other stem cells.

"As a company, TSOI is highly interested in inflammatory processes associated with COVID-19, in fact, we are unique in being one of the only companies that is concurrently developing cellular therapies while running clinical trials on nutraceutical approaches to COVID-193" said Famela Ramos, Director of Business Development.

"It has been my pleasure to work with Timothy Dixon and his scientific team in advancing the basic science surrounding JadiCells, and the clinical translation for treatment of brain pathologies" said Amit Patel, MD, MSc, inventor of the JadiCell. "By supplying our cells to groups such as University of Miami, or Therapeutic Solutions International, we believe we can hyper accelerate the development of this novel stem cell, and hopefully save some lives."

"I applaud the brave doctors which have implemented the novel use of JadiCells in treatment of COVID-19. It is an honor to work with Dr. Patel in what we anticipate will be another success for this cell type in addressing areas of unmet medical needs" said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Brain injuries and CTE take a terrible toll not only in our athletes, but also our soldiers and veterans, contributing to suicide and other pathologies. We are excited to utilize JadiCells in treating one of the last frontiers of medicine. the brain."

About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875 2https://www.globenewswire.com/news-release/2019/07/01/1876699/0/en/Therapeutic-Solutions-International-2Obtains-Exclusive-License-for-Patented-Clinical-Stage-Adult-Stem-Cell-for-Treatment-of-Military-and-Sports-Brain-Injuries.html 3https://www.clinicaltrials.gov/ct2/show/NCT04421391

ir@tsoimail.com

View original content:http://www.prnewswire.com/news-releases/jadicell-stem-cells-licensed-by-therapeutic-solutions-international-for-brain-injury-significantly-increased-survival-of-covid-19-patients-in-double-blind-fda-clinical-trial-301161910.html

SOURCE Therapeutic Solutions International

Read this article:
JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double...

Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 – PRnews Leader

Overview for Adult Stem Cells Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

Adult Stem Cells Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024 The study of Adult Stem Cells market is a compilation of the market of Adult Stem Cells broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Adult Stem Cells industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Adult Stem Cells industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Adult Stem Cells Market report @ https://hongchunresearch.com/request-a-sample/92343

Key players in the global Adult Stem Cells market covered in Chapter 4: Intellicell Biosciences Inc. Globalstem Neurogeneration Capricor Inc. Caladrius Biosciences Inc. Mesoblast Ltd. Celyad Juventas Therapeutics Inc. Cytori Therapeutics Inc. Cellular Dynamics International Epistem Ltd. Brainstorm Cell Therapeutics Inc. Cellerant Therapeutics Inc. Hybrid Organ Gmbh Cellerix Sa Neuralstem International Stem Cell Corp. Beike Biotechnology Co. Ltd. Biotime Inc. Gamida Cell Ltd. Clontech

In Chapter 11 and 13.3, on the basis of types, the Adult Stem Cells market from 2015 to 2026 is primarily split into: Epithelial Stem Cells Hematopoietic Stem Cells

In Chapter 12 and 13.4, on the basis of applications, the Adult Stem Cells market from 2015 to 2026 covers: Neurodegenerative Diseases Heart Diseases Bone Diseases Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13: North America (Covered in Chapter 6 and 13) United States Canada Mexico Europe (Covered in Chapter 7 and 13) Germany UK France Italy Spain Russia Others Asia-Pacific (Covered in Chapter 8 and 13) China Japan South Korea Australia India Southeast Asia Others Middle East and Africa (Covered in Chapter 9 and 13) Saudi Arabia UAE Egypt Nigeria South Africa Others South America (Covered in Chapter 10 and 13) Brazil Argentina Columbia Chile Others

For a global outreach, the Adult Stem Cells study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses: Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions Revenue, cost price, capacity & utilizations, import/export rates and market share Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Adult Stem Cells Market Report with [emailprotected]https://hongchunresearch.com/report/adult-stem-cells-market-size-2020-92343

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Adult Stem Cells Market

Chapter Four: Players Profiles

Chapter Five: Global Adult Stem Cells Market Analysis by Regions

Chapter Six: North America Adult Stem Cells Market Analysis by Countries

Chapter Seven: Europe Adult Stem Cells Market Analysis by Countries

Chapter Eight: Asia-Pacific Adult Stem Cells Market Analysis by Countries

Chapter Nine: Middle East and Africa Adult Stem Cells Market Analysis by Countries

Chapter Ten: South America Adult Stem Cells Market Analysis by Countries

Chapter Eleven: Global Adult Stem Cells Market Segment by Types

Chapter Twelve: Global Adult Stem Cells Market Segment by Applications 12.1 Global Adult Stem Cells Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Adult Stem Cells Sales and Market Share by Applications (2015-2020) 12.1.2 Global Adult Stem Cells Revenue and Market Share by Applications (2015-2020) 12.2 Neurodegenerative Diseases Sales, Revenue and Growth Rate (2015-2020) 12.3 Heart Diseases Sales, Revenue and Growth Rate (2015-2020) 12.4 Bone Diseases Sales, Revenue and Growth Rate (2015-2020) 12.5 Others Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Adult Stem Cells Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/92343

List of tables List of Tables and Figures Table Global Adult Stem Cells Market Size Growth Rate by Type (2020-2026) Figure Global Adult Stem Cells Market Share by Type in 2019 & 2026 Figure Epithelial Stem Cells Features Figure Hematopoietic Stem Cells Features Table Global Adult Stem Cells Market Size Growth by Application (2020-2026) Figure Global Adult Stem Cells Market Share by Application in 2019 & 2026 Figure Neurodegenerative Diseases Description Figure Heart Diseases Description Figure Bone Diseases Description Figure Others Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Adult Stem Cells Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Adult Stem Cells Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Adult Stem Cells Figure Production Process of Adult Stem Cells Figure Manufacturing Cost Structure of Adult Stem Cells Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Intellicell Biosciences Inc. Profile Table Intellicell Biosciences Inc. Production, Value, Price, Gross Margin 2015-2020 Table Globalstem Profile Table Globalstem Production, Value, Price, Gross Margin 2015-2020 Table Neurogeneration Profile Table Neurogeneration Production, Value, Price, Gross Margin 2015-2020 Table Capricor Inc. Profile Table Capricor Inc. Production, Value, Price, Gross Margin 2015-2020 Table Caladrius Biosciences Inc. Profile Table Caladrius Biosciences Inc. Production, Value, Price, Gross Margin 2015-2020 Table Mesoblast Ltd. Profile Table Mesoblast Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Celyad Profile Table Celyad Production, Value, Price, Gross Margin 2015-2020 Table Juventas Therapeutics Inc. Profile Table Juventas Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cytori Therapeutics Inc. Profile Table Cytori Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cellular Dynamics International Profile Table Cellular Dynamics International Production, Value, Price, Gross Margin 2015-2020 Table Epistem Ltd. Profile Table Epistem Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Brainstorm Cell Therapeutics Inc. Profile Table Brainstorm Cell Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cellerant Therapeutics Inc. Profile Table Cellerant Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Hybrid Organ Gmbh Profile Table Hybrid Organ Gmbh Production, Value, Price, Gross Margin 2015-2020 Table Cellerix Sa Profile Table Cellerix Sa Production, Value, Price, Gross Margin 2015-2020 Table Neuralstem Profile Table Neuralstem Production, Value, Price, Gross Margin 2015-2020 Table International Stem Cell Corp. Profile Table International Stem Cell Corp. Production, Value, Price, Gross Margin 2015-2020 Table Beike Biotechnology Co. Ltd. Profile Table Beike Biotechnology Co. Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Biotime Inc. Profile Table Biotime Inc. Production, Value, Price, Gross Margin 2015-2020 Table Gamida Cell Ltd. Profile Table Gamida Cell Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Clontech Profile Table Clontech Production, Value, Price, Gross Margin 2015-2020 Figure Global Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Global Adult Stem Cells Revenue ($) and Growth (2015-2020) Table Global Adult Stem Cells Sales by Regions (2015-2020) Table Global Adult Stem Cells Sales Market Share by Regions (2015-2020) Table Global Adult Stem Cells Revenue ($) by Regions (2015-2020) Table Global Adult Stem Cells Revenue Market Share by Regions (2015-2020) Table Global Adult Stem Cells Revenue Market Share by Regions in 2015 Table Global Adult Stem Cells Revenue Market Share by Regions in 2019 Figure North America Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Europe Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Asia-Pacific Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Middle East and Africa Adult Stem Cells Sales and Growth Rate (2015-2020) Figure South America Adult Stem Cells Sales and Growth Rate (2015-2020) Figure North America Adult Stem Cells Revenue ($) and Growth (2015-2020) Table North America Adult Stem Cells Sales by Countries (2015-2020) Table North America Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure North America Adult Stem Cells Sales Market Share by Countries in 2015 Figure North America Adult Stem Cells Sales Market Share by Countries in 2019 Table North America Adult Stem Cells Revenue ($) by Countries (2015-2020) Table North America Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure North America Adult Stem Cells Revenue Market Share by Countries in 2015 Figure North America Adult Stem Cells Revenue Market Share by Countries in 2019 Figure United States Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Canada Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Mexico Adult Stem Cells Sales and Growth (2015-2020) Figure Europe Adult Stem Cells Revenue ($) Growth (2015-2020) Table Europe Adult Stem Cells Sales by Countries (2015-2020) Table Europe Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure Europe Adult Stem Cells Sales Market Share by Countries in 2015 Figure Europe Adult Stem Cells Sales Market Share by Countries in 2019 Table Europe Adult Stem Cells Revenue ($) by Countries (2015-2020) Table Europe Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure Europe Adult Stem Cells Revenue Market Share by Countries in 2015 Figure Europe Adult Stem Cells Revenue Market Share by Countries in 2019 Figure Germany Adult Stem Cells Sales and Growth Rate (2015-2020) Figure UK Adult Stem Cells Sales and Growth Rate (2015-2020) Figure France Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Italy Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Spain Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Russia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Asia-Pacific Adult Stem Cells Revenue ($) and Growth (2015-2020) Table Asia-Pacific Adult Stem Cells Sales by Countries (2015-2020) Table Asia-Pacific Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Adult Stem Cells Sales Market Share by Countries in 2015 Figure Asia-Pacific Adult Stem Cells Sales Market Share by Countries in 2019 Table Asia-Pacific Adult Stem Cells Revenue ($) by Countries (2015-2020) Table Asia-Pacific Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Adult Stem Cells Revenue Market Share by Countries in 2015 Figure Asia-Pacific Adult Stem Cells Revenue Market Share by Countries in 2019 Figure China Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Japan Adult Stem Cells Sales and Growth Rate (2015-2020) Figure South Korea Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Australia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure India Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Southeast Asia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Middle East and Africa Adult Stem Cells Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer Gray Manager Global Sales + 852 8170 0792 [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Visit link:
Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 - PRnews Leader

APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of…

October 28, 2020 20:08 ET | Source: APstem Therapeutics

Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included CBER OTAT staff together with the APstem team, focused on the development plan for AP-Skin-01, a novel off-the-shelf allogeneic stem cell product derived from adult pluripotent stem cells (APSCs) for the initial treatment of diabetic ulcers.

Previous efforts to treat diabetic ulcers have been hampered by persistent inflammation, ischemia and delayed re-epithelialization, which together have posed an insurmountable challenge for drug developers. APstems proprietary stem cell technologies and unique attributes of APSCs may circumvent these obstacles. Preclinical results generated to date by APstem support the potential of AP-Skin-01 to treat difficult-to-heal diabetic ulcers by accelerating healing. AP-Skin-01 is designed to provide full skin structural reconstruction with less scar formation, promote angiogenesis and reduce inflammation during the repair process.

The INTERACT meeting we conducted with the FDA is an important first step in our development of AP-Skin-01. We considered the meeting to be very successful, with productive feedback from the FDA reviewers and strong alignment of APstems development approach for AP-Skin-01, said Dr. Min Hu, CEO and president of APstem Therapeutics. I would like to thank the reviewers from FDA CBER OTAT for their time and helpful guidance. We look forward to continuing our planned pre-clinical work into 2021.

Dr. Jane Lebkowski, APstems scientific advisor and an expert in the development of cell and gene therapies, added: The field of chronic diabetic wounds remains a critical unmet medical need in the expanding diabetic population worldwide. This new therapy has high potential to accelerate full skin regeneration. Therefore, we are grateful for FDAs positive feedback to accelerate the development of this product that could treat millions of patients.

INTERACT is the first available FDA interaction and is a key step in the pathway towards an Investigational New Drug (IND) application, the first regulatory step before experimental therapies may be tested in human clinical studies.

About APstem Therapeutics, Inc.

APstem Therapeutics is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing novel stem cell therapies. APstems breakthrough stem cell therapy platform using our unique APSCs can be applied to multiple indications, including skin (diabetic ulcers), liver, lungs, bone/cartilage, heart, neuron and other tissues. For more information, please visit http://www.apstemtx.com.

Fremont, California, UNITED STATES

https://www.apstemtx.com/

Formats available:

Follow this link:
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of...

Why Small Businesses Matter in Wilton (Reimagined): Interventional Orthopedics Connecticut – HamletHub

Small businesses matter - now more than ever. They are answering the call with innovation and determination like never before.

We hope you join us in supporting them by sharing their story far and wide and shopping local! We are thankful to Fairfield County Bank for their continued support and making this series possible.

Step insideInterventional Orthopedics Connecticut!

Three questions with Daniel Southern, founder ofInterventional Orthopedics Connecticut.

_____________________________________________________________________________

What do you want the community to know? Are there ways for the community to help you and other local businesses to prosper?

Interventional Orthopedics treats orthopedic injuries and arthritis in a novel fashion using your bodys own repair mechanisms.

The bodys repair mechanism is contained in the cells of your body, specifically small cells in your blood called platelets and cells that we get from your bones called adult stem cells. We take these cells, concentrate them, and place them back in the body via injections very precisely into areas of damage.

When this works, surgery is not necessary. We are repairing tendon and ligament tears, meniscal and rotator cuff tears with precise injections of highly concentrated cells that we take from a simple blood draw out of your arm.

There is no cure for arthritis but the work we are doing can stop the pain of arthritis and dramatically slow its progression to the point where patients who were told that their only option was joint replacement are living happily with their own joints intact following our treatment.

Are you offering any new products or ways for customers to purchase your products or services that are popular during this crisis?

We are offering telemedicine evaluations that keep you safe at home while we can do a full evaluation of your issues to determine if you are a candidate for treatment. This is most effective if you already have imaging of your painful hip, knee, neck, shoulder, or back. If that is the case, we can go over the film with you at a Zoom meeting and discuss treatment options. If not, we can order them for you and meet again remotely to discuss them.

Please share the ways your business is adapting to keep your customers and employees safe in addition to the standard guidelines

We are offering our patients several options for any procedures that we recommend that will keep them out of high-traffic institutions such as a hospital waiting room or operating room or large clinical practice. We do many of our straight-forward ligament, tendon, and joint injections in the office with oral sedation and local anesthetic. For more involved cases or if the patient prefers IV anesthesia, we use the Wilton Surgery Center downstairs with strict safety protocols including every patient tested daily for Covid.

Our clinic has instituted a Maximum Protection Zone for patient and employee safety. In addition to the standard masks and social distancing, we test staff weekly for Covid-19 to make sure you are not exposed by us. We allow only two patients in the clinic at a time, one in each exam room or one in a room and one in the waiting area. All the air is continuously filtered with HEPA rated filters to remove any airborne viral particles. The exam rooms are blasted with UV light for 15 minutes between patients, again, to kill any airborne or surface viral particles. All surfaces in the exam room and front desk area are wiped clean using a laboratory-grade disinfectant.

Interventional Orthopedics Connecticut is located at195 Danbury Rd. in Wilton -Whitlock Building (second building) Suite B220 (second floor). Visit Interventional Orthopedics Connecticut online here, and also make sure to check out their Facebook page as well!

Daniel Southern nominatesDynamic Edge Physical Therapy from Wilton!

HamletHub thanksFairfield County Bankfor making our Why Small Businesses Matter series possible!

Go here to read the rest:
Why Small Businesses Matter in Wilton (Reimagined): Interventional Orthopedics Connecticut - HamletHub